Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 19

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 19
---
              |      — |     |                |       — |
| Total stockholders’ (deficit) equity   |     |                     | (103,873 | ) |     |              | 10,386 |     |                | 238,886 |

| (1) | The pro forma balance sheet data gives effect to (i) the automatic conversion of all of our outstanding                                                                                                                                                   
 shares of redeemable convertible preferred stock into an aggregate of 3,181,815 shares of common stock immediately upon the closing of this offering and the related reclassification of the carrying value of the redeemable convertible preferred stock 
 and preferred stock warrant liability to stockholders’ equity upon the closing of this offering and (ii) the filing of our amended and restated certificate of incorporation immediately prior to the closing of this offering.                           |

| (2) | The pro forma as adjusted balance sheet data gives effect to (i) the pro forma adjustments set forth in                                                                                                                                                 
 footnote (1) above and (ii) the issuance and sale of 16,666,667 shares of common stock in this offering at the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page          
 of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share would increase (decrease) 
 each of our pro forma as adjusted cash and cash equivalents and marketable securities, total assets, working capital, and total stockholders’ (deficit) equity by approximately $15.5 million, assuming that the number of shares offered, as set       
 forth on the cover of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions payable by us. Each increase (decrease) of 1.0 million shares in the number of shares offered by us would increase     
 (decrease) each of our pro forma cash and cash equivalents and marketable securities, total assets, working capital, and total stockholders’ (deficit) equity by approximately $14.0 million, assuming the assumed initial public offering price        
 per share remains the same and after deducting the estimated underwriting discounts and commissions payable by us.                                                                                                                                      |

| (3) | This pro forma as adjusted information is illustrative only and will depend on the actual initial public 
 offering price and other terms of this offering